Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
about
CD20-Mimotope Peptide Active Immunotherapy in Systemic Lupus Erythematosus and a Reappraisal of Vaccination Strategies in Rheumatic Diseases.Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura.Regulation of immunity by anti-T-cell antibodies.Marrow transplantation from tolerant donors to treat and prevent autoimmune diseases in BXSB miceNew approaches to treating systemic lupus erythematosusPrevention of diabetes in nonobese diabetic mice by anti-I-A monoclonal antibodies: transfer of protection by splenic T cellsLessons from the NZM2410 model and related strains.Strategies for treating autoimmune disease with monoclonal antibodies.Genetic analysis of the imperfect association of H-2 haplotype with lupus-like autoimmune disease.Increased expression of major histocompatibility complex antigens on lymphocytes from aged mice.Sequence analysis and structure-function correlations of murine q, k, u, s, and f haplotype I-A beta cDNA clones.Enhanced MHC class II expression in renal proximal tubules precedes loss of renal function in MRL/lpr mice with lupus nephritisDexamethasone prevents autoimmune nephritis and reduces renal expression of Ia but not costimulatory signals.Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferonPrevention of nephritis in major histocompatibility complex class II-deficient MRL-lpr mice.Holes in the T cell repertoire to myelin basic protein owing to the absence of the D beta 2-J beta 2 gene cluster: implications for T cell receptor recognition and autoimmunity.Monoclonal anti-I-A antibody reverses chronic paralysis and demyelination in Theiler's virus-infected mice: critical importance of timing of treatment.In vivo prevention of thyroid and pancreatic autoimmunity in the BB rat by antibody to class II major histocompatibility complex gene products.Influence of early or late dietary restriction on life span and immunological parameters in MRL/Mp-lpr/lpr mice.Cytokines in the pathophysiology of systemic lupus erythematosus.Rational design and application of idiotope vaccines.Premises for immune interventional therapy in rheumatoid arthritisIn vivo effects of antibodies to immune response gene products. II. Suppression of humoral immune responses with monoclonal anti-I-A is due to suppressor cells.New concepts in autoimmunity.Genetic contributions to lupus-like disease in (NZB x NZW)F1 mice.Remission of rheumatoid arthritis during pregnancy and maternal-fetal class II alloantigen disparity.Lactic dehydrogenase virus infection prevents development of anti-nuclear antibody in (NZB x NZW)F1 mice; role of prostaglandin E2 and macrophage Ia antigen expression.Repression of major histocompatibility complex IA expression by glucocorticoids: the glucocorticoid receptor inhibits the DNA binding of the X box DNA binding protein.The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice.A unique sequence of the NZW I-E beta chain and its possible contribution to autoimmunity in the (NZB x NZW)F1 mouse.Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.Treatment of experimental autoimmune myasthenia gravis with monoclonal antibodies to immune response gene products.Use of anti-thymocyte globulin in the management of refractory systemic autoimmune diseases.
P2860
Q30388433-1B77D8EC-2233-44EA-A0A1-B2D18AEB75CAQ33410674-E17E4A89-F8AD-47DF-991B-527AD6C35A46Q33558513-0808DB34-A982-439B-B909-C28B8CD52C5CQ33563759-1344E06D-FD13-4237-BB2C-761CDEDB6945Q33614633-2605CCE0-8764-40EC-8415-389CE8EE8151Q33687787-71B02811-8CA0-43F9-A707-BB27AA21B9DEQ34051998-16661E62-FFF1-4907-9940-8E359B26BDEAQ34193193-D5C00036-CE64-46F5-BAC8-5D5A880662EEQ34308440-331729BF-ACCA-4C5D-9663-A78C9F478B79Q34359781-F6594C20-B40A-4957-8336-F6F07CB5C9DFQ35607095-1B4D2ABA-A21C-42F1-9F78-7C2B6F94E0CEQ35816089-3C328F9F-EC75-4045-8185-BF75FD581805Q35832151-6AB16D91-5095-48E3-89D9-E5ED6E0C84B2Q35837746-AD27F123-F6A7-437D-A9BD-05B0043B3CBFQ36349869-D7CA4084-FFF2-40E5-9644-BB07A6E307BFQ36353914-1EFF3069-9A9C-4151-8F75-3F13837B88CFQ36362973-76EC5787-D09F-4EEC-8B3E-D48EEF1B4744Q36363078-21C7C808-B30B-4D67-95C4-1052E4635601Q36885823-1224D550-FC1C-4407-9158-4DA6BAE50340Q37550942-EB7F8A01-D3AF-4CA0-9178-86565BEEBEB9Q37568656-86B5E443-8BEE-4AAE-9F3E-F3104CAF8B63Q37805978-FFDE1A4F-6B8D-46B5-8C16-B36F24FFFD64Q38204525-8E7567A2-2A4C-47F8-95EE-750CF98AE8B6Q39185484-EA9FD542-E997-4358-9ECA-06C707ABEA83Q39330732-69837038-122F-4E3A-9213-888D6AB84F68Q39591098-16CF9537-1380-4E0A-8E3D-F46AB6D5EF0EQ40433254-DA4B7D59-750D-4E3E-BC4E-7B5377FCFF4BQ41079482-D876218E-7620-4D55-9FF0-DE590A0342E8Q41156462-37908CD6-FD98-4809-B366-72F73D206F85Q41570362-28F1185E-4EFE-44AB-9C35-4A14C0CB20C2Q42019842-8AA8E73F-E3A2-4921-98BD-2FC123260479Q42939797-EAF6AA11-ABA5-45A3-964C-398F18CE2F20Q46273645-C2F60D42-9052-4890-B5EF-2745D6C40054Q46313473-C25FCE75-5866-46A1-B520-2C1B933C1F90Q54253553-81CBA163-58D4-474F-86DF-041883D198B8
P2860
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh
1983年學術文章
@zh-hant
name
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
@ast
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
@en
type
label
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
@ast
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
@en
prefLabel
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
@ast
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
@en
P2093
P2860
P356
P1476
Treatment of (NZB x NZW)F1 disease with anti-I-A monoclonal antibodies.
@en
P2093
D L Watling
H O McDevitt
N E Adelman
P2860
P304
P356
10.1084/JEM.158.4.1350
P407
P577
1983-10-01T00:00:00Z